局部晚期宫颈癌新预后肿瘤评分:整合临床检查与MRI
研究纳入400例2005–2018年接受放化疗和图像引导自适应近距离放疗的局部晚期宫颈癌患者,基于临床检查与MRI对8个解剖部位按0–3分排序评分构建肿瘤评分(T-score)。T-score分组在单因素和多因素分析中均显著,对生存和局部控制的预测优于FIGO分期,并可预测IGABT靶体积、插植针使用及剂量参数。
要点
- T-score整合临床检查与MRI,对8个解剖部位按0–3分评分。
- T-score分组对生存和局部控制的预测优于FIGO 2009分期。
- T-score可预测IGABT靶体积、插植针使用和剂量参数。
核心结论
- T-score是整合临床与影像的简易工具,对生存和局部控制具有超越传统分期的预后能力。
- T-score在诊断时即可预测关键IGABT参数,并可用于多中心审计和结果比较。
研究设计与样本
- 研究为单中心连续病例分析,纳入400例2005至2018年接受放化疗和图像引导自适应近距离放疗的局部晚期宫颈癌患者。
- 诊断检查包括临床检查、正电子发射断层扫描/计算机断层扫描和MRI。
- FIGO 2009分期分布为IB–IIA 9%、IIB 61%、III–IV 30%。
主要发现
- T-score中位数为6(范围0–20),按频率分布分为0–4、5–6、7–9和>9四组。
- T-score分组在单因素和多因素分析中均高度显著,对生存和局部控制的预测优于FIGO分期,并支持分期内预后分层。
- T-score作为线性变量与IGABT靶体积(高危临床靶体积,CTVHR)、插植针使用、CTVHR D90和总参考空气比释动能相关。
关键数值与推荐
- 对宫颈、左宫旁、右宫旁、阴道、膀胱、输尿管、直肠和宫体共8个解剖部位,按0–3分排序量表评分,总分构成T-score。
- T-score按频率分布分为0–4、5–6、7–9和>9四组。
临床怎么用
- 可在诊断时用T-score整合临床与MRI信息进行预后分层,辅助识别高危患者。
- T-score可预测IGABT靶体积和插植针需求,有助于提前规划近距离放疗资源。
- T-score可用于多中心结果审计和比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The integral results of clinical examination and magnetic resonance imaging (MRI) of patients with locally advanced cervical cancer may provide prognostic information that cannot readily be placed in current staging systems, such as proximal versus distal parametrial invasion, unilateral versus bilateral involvement, or organ infiltration on MRI. The aim was to develop and investigate the performance of a simple but comprehensive tumor score for reporting and prognostication. METHODS AND MATERIALS: In the present study, 400 consecutive patients with locally advanced cervical cancer treated 2005 to 2018 with chemoradiation and image guided adaptive brachytherapy (IGABT) were analyzed. The diagnostic workup included clinical examination, positron emission tomography/computed tomography, and MRI. International Federation of Gynecology and Obstetrics 2009 stage distribution was IB to IIA 9%, IIB 61%, and III to IV 30%. Involvement of 8 anatomic locations (cervix, left parametrium, right parametrium, vagina, bladder, ureter, rectum, and uterine corpus) was scored according to a ranked ordinal scale with 0 to 3 points. The total sum of points constituted the tumor score (T-score). RESULTS: The median T-score was 6 (range, 0-20). Based on the frequency distribution of the T-score, 4 equally sized groups were formed: 0 to 4, 5 to 6, 7 to 9, and >9 points. The T-score grouping was highly significant in both univariate and multivariable analysis and outperformed International Federation of Gynecology and Obstetrics stage for both survival and local control enabling also intrastage prognostication. Used as a linear variable, the T-score was correlated with IGABT target volume (high-risk clinical target volume, CTVHR), use of interstitial needles, dose (D90 of CTVHR), and total reference air kerma. CONCLUSIONS: The T-score is a simple instrument for combining clinical findings and imaging into a powerful prognostic factor for survival and local control with capabilities surpassing traditional staging. In addition, the T-score may already at diagnosis predict essential IGABT parameters and may be used for audit and comparison of results in multicenter settings.
引用
- Lindegaard JC, Petric P, Lindegaard AM, et al. Evaluation of a New Prognostic Tumor Score in Locally Advanced Cervical Cancer Integrating Clinical Examination and Magnetic Resonance Imaging. Int J Radiat Oncol Biol Phys. 2019. PMID: 31794837. doi:10.1016/j.ijrobp.2019.11.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。